Evaluation of human platelet lysate (hpl) as a substitute for foetal bovine serum (fbs) and recombinant proteins for the growth and maintenance of bone marrow derived mesenchymal stromal cells (bm-msc)

ConclusionThe growth and phenotype of BM-MSC cultured in either apheresis HPL or commercial HPL were comparable, suggesting apheresis HPL may prove a suitable alternative to FBS. A simpler preparation protocol of HPL for the end users will increase the likelihood of introducing HPL into current laboratory practice. The potential of pooled HPL warrants further investigation.
Source: Cytotherapy - Category: Cytology Source Type: research